| Reserpine | 608.6787
C33H40N2O9 |  | For the treatment of hypertension | Secologanin Tryptamine Alkaloids |
| Diosmin | 608.5447
C28H32O15 |  | A citrus flavonoid medication used to support vascular health. | Flavonoids |
| Fulvestrant | 606.78
C32H47F5O3S |  | An estrogen receptor antagonist used to treat HR+ breast cancer that may also be HER2-. | Anti-Estrogens |
| Gadobutrol | 604.72
C18H31GdN4O9 |  | A gadolinium-based contrast agent (GBCA) used with contrasted magnetic resonance imaging (MRI) to detect and visualize lesions and abnormal vascularity. | Paramagnetic Contrast Media |
| Adagrasib | 604.13
C32H35ClFN7O2 |  | A KRAS inhibitor indicated for the treatment of locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer in patients who have received at least one prior systemic therapy. | Antineoplastic Agents |
| Benzonatate | 603.7419
C30H53NO11 |  | A non-narcotic oral antitussive drug used to suppress coughing. | Antitussive Agents / Non-narcotic Antitussive |
| Atogepant | 603.525
C29H23F6N5O3 |  | An oral CGRP antagonist used for the preventative therapy of episodic migraine headaches. | Calcitonin Gene-Related Peptide Receptor Antagonists |
| Tetrakis(2-methoxyisobutylisocyanide)copper(I) tetrafluoroborate | 602.99
C24H44BCuF4N4O4 |  | Tetrakis (2-methoxyisobutylisocyanide) copper (I) tetrafluoroborate is a component of Cardiolite, a technetium Tc99m-based imaging agent used for assessing myocardial perfusion. | Not Annotated |
| Pipecuronium | 602.8912
C35H62N4O4 |  | A nondepolarizing neuromuscular blocking agent used to relax muscles during anesthesia and surgical procedures. | Agents producing tachycardia |
| Tipranavir | 602.664
C31H33F3N2O5S |  | A protease inhibitor used to treat HIV-1 resistant to more than 1 protease inhibitor. | Anti-HIV Agents / Drugs causing inadvertant photosensitivity / Protease Inhibitors |
| Lymecycline | 602.6328
C29H38N4O10 |  | A tetracycline antibiotic used for the treatment of acne vulgaris and other susceptible infections. | Tetracyclines |
| Remdesivir | 602.585
C27H35N6O8P |  | A nucleoside analog used to treat RNA virus infections including COVID-19. | Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors |
| Pentosan polysulfate | 602.497
C10H18O21S4 |  | A sulfated pentosyl polysaccharide used to treat bladder pain and discomfort due to interstitial cystitis. | Anticoagulants / Drugs causing inadvertant photosensitivity / Glycosaminoglycans / Polysaccharides / Sulfuric Acids |
| Iopodic acid | 597.961
C12H13I3N2O2 |  | An iodine containing cholecystography agent. | Watersoluble, Hepatotropic X-Ray Contrast Media |
| Rapacuronium | 597.904
C37H61N2O4 |  | A nondepolarizing neuromuscular blocking agent used as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures. | Agents producing tachycardia |
| Revefenacin | 597.76
C35H43N5O4 |  | An anticholinergic agent used to treat COPD. | Anticholinergic Agents / Bronchodilator Agents / Muscarinic Antagonists |
| Elexacaftor | 597.66
C26H34F3N7O4S |  | A small molecule CFTR corrector used in combination with tezacaftor and ivacaftor for the treatment of cystic fibrosis patients with one F508del-CFTR mutation. | Cystic Fibrosis Transmembrane Conductance Regulator Correctors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Membrane Transport Modulators / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates |
| Lotilaner | 596.75
C20H14Cl3F6N3O3S |  | An antiparasitic agent used to treat Demodex blepharitis. | Antiparasitic Agents / Ectoparasiticide / Ectoparasiticides, Incl. Scabicides / Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents / Sulfur Compounds |
| Sultamicillin | 594.65
C25H30N4O9S2 |  | A mutual prodrug of ampicillin and sulbactam useful in the treatment of infections caused by beta-lactamase-producing bacteria. | Anti-Bacterial Agents |
| Sparsentan | 592.76
C32H40N4O5S |  | An endothelin and angiotensin II receptor antagonist indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. | Agents Acting on the Renin-Angiotensin System / Amides / Angiotensin 2 Receptor Blocker / Angiotensin II receptor antagonists / Angiotensin II Type 1 Receptor Blockers / Angiotensin Receptor Antagonists / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Dual Endothelin Type A Receptor/Ang II Subtype 1 Receptor Antagonist (DEARA) / Endothelin Receptor Antagonists / OAT3/SLC22A8 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates / Sulfones / Sulfur Compounds |
| Plazomicin | 592.691
C25H48N6O10 |  | An aminoglycoside antibiotic used to treat complicated urinary tract infections. | Agents that produce neuromuscular block (indirect) / Aminoglycoside Antibacterials / Anti-Bacterial Agents / Antibacterials for Systemic Use / Antiinfectives for Systemic Use / Carbohydrates / Drugs that are Mainly Renally Excreted / Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index / Gentamicins / Glycosides / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Narrow Therapeutic Index Drugs / Nephrotoxic agents |
| Hexobendine | 592.686
C30H44N2O10 |  | Hexobendine is a medication used to cause vasodilation, to treat several conditions including angina pectoris. It has not been approved in the United States or the United Kingdom, but has... | Hydroxybenzoate Ethers / Vasodilating Agents |
| Calcium glubionate anhydrous | 592.513
C18H32CaO19 |  | A calcium salt indicated in the treatment of hypocalcemia, hyperkalemia, lead poisoning, and as an adjunct in the treatment of exudative skin conditions. | Calcium Salts |
| Lusutrombopag | 591.54
C29H32Cl2N2O5S |  | A medication used to treat thrombocytopenia in patients with chronic liver disease scheduled to have a procedure. | Acids, Carbocyclic / BCRP/ABCG2 Substrates / Blood and Blood Forming Organs / Hemostatics / P-glycoprotein substrates / Sulfur Compounds / Thrombopoietin Receptor Agonist |
| Etoposide | 588.5566
C29H32O13 |  | A podophyllotoxin derivative used to treat testicular and small cell lung tumors. | Podophyllotoxin Derivatives |
